BMY will pay BBIO $90 million in upfront cash.
The company is developing treatments for serious genetic diseases, with an initial focus on neuromuscular diseases.
The company is waiting on FDA review of its lead product candidate.
Biogen will also halt marketing of Aduhelm.
We think opportunities abound in the sector.
The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.
The company will merge with Isleworth Healthcare Acquisition Corp.
Paxlovid may be the most potent COVID-19 therapy currently available.
Coeptis is developing novel cell therapy platforms for cancer.
The financing will support the commercialization of BioXcel's recently approved Igalmi sublingual film for agitation associated with schizophrenia or bipolar I or II disorder.
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
